Chronic Lymphocytic Leukemia Clinical Trials

A listing of 71 Chronic Lymphocytic Leukemia clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Chronic Lymphocytic Leukemia

25 - 36 of 71

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 71 active clinical trials seeking participants for Chronic Lymphocytic Leukemia research studies. The states with the highest number of trials for Chronic Lymphocytic Leukemia participants are California, Ohio, Illinois and Michigan.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

NCT01890486

Recruiting

To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

05/28/2025

Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Germ Cell Neoplasms, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immunodeficiency Diseases

Learn More ›

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

NCT06001385

Recruiting

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Mayo Clinic Arizona, Phoenix, Arizona +31 locations

Mayo Clinic Arizona, Phoenix, Arizona

Honor Health, Scottsdale, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

City of Hope, Duarte, California

University of California San Francisco, San Francisco, California

Stanford University, Stanford, California

Colorado Blood Cancer Institute at Presbyterian St. Luke's, Denver, Colorado

Mayo Clinic Jacksonville, Jacksonville, Florida

University of Miami Sylvester Cancer Center, Miami, Florida

Moffitt Cancer Center, Tampa, Florida

Emory University, Atlanta, Georgia

Greenbaum Cancer Center University of Maryland, Baltimore, Maryland

Tufts University, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

University of Minnesota, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

Barnes Jewish Hospital / Washington University, Saint Louis, Missouri

Memorial Sloan Kettering Cancer Center - Adults, New York, New York

University of North Carolina, Chapel Hill, North Carolina

Ohio State Medical Center, Columbus, Ohio

Oregon Health & Science University, Portland, Oregon

The Center for Bone Marrow Transplantation at Geisinger, Danville, Pennsylvania

Abramson Cancer Center, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

TriStar Centennial, Nashville, Tennessee

St. David's South Austin Medical Center, Austin, Texas

MD Anderson Cancer Center, Houston, Texas

Methodist Hospital San Antonio, San Antonio, Texas

University of Virginia Health System, Charlottesville, Virginia

Fred Hutchinson Cancer Center, Seattle, Washington

Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis

Learn More ›

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

NCT06839053

Recruiting

This phase II trial studies the side effects of an escalated ramp-up of sonrotoclax following initial debulking with zanubrutinib or rituximab in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL) that is newly diagnosed, has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Rituximab is a monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma

Learn More ›

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT06533579

Recruiting

This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

Gender:

ALL

Ages:

Between 13 years and 90 years

Trial Updated:

05/27/2025

Locations: City of Hope, Duarte, California +6 locations

Conditions: B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia

Learn More ›

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686

Recruiting

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: City of Hope Cancer Center, Duarte, California +173 locations

City of Hope Cancer Center, Duarte, California

University of California San Diego Medical Center, La Jolla, California

University of California Los Angeles, Los Angeles, California

St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange, California

Stanford University Medical Center, Stanford, California

Stanford University, Stanford, California

Norwalk Medical Group, Norwalk, Connecticut

Northwest Georgia Oncology Centers PC, Marietta, Georgia

Northwestern University Hospital, Chicago, Illinois

Indiana University, Goshen, Indiana

Kansas University Medical Center, Westwood, Kansas

Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky

Dana Farber Cancer Center, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Battle Creek Health Systm, Battle Creek, Michigan

Karmanos Cancer Institute - Wayne State University, Detroit, Michigan

Washington University, Saint Louis, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Hackensack University Medical Center, Hackensack, New Jersey

Weill Medical College of Cornell University, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Southeastern Medical Oncology Center, Goldsboro, North Carolina

The Ohio State University- James Cancer Hospital, Columbus, Ohio

Willamette Valley Cancer Center, Eugene, Oregon

Kaiser Permanente, Portland, Oregon

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Avera Medical Group, Sioux Falls, South Dakota

MD Anderson Cancer Center - University of Texas, Houston, Texas

University of Virginia, Charlottesville, Virginia

University of Washington, Seattle, Washington

West Virginia University, Morgantown, West Virginia

University of Wisconsin Carbone Cancer Center - Wisconsin Institute for Medical Research, Madison, Wisconsin

CEMIC Saavedra, Ciudad Autonoma Buenos Aires, Not set

Fundaleu, Ciudad de Buenos Aires, Not set

Royal Adelaide Hospital, Adelaide, Not set

John Fawkner Cancer Trial Centre, Coburg, Not set

Concord Hospital, Concord, Not set

Austin Health, Heidelberg, Not set

Peter MacCallum Cancer Institute, Melbourne, Not set

Royal Perth Hospital, Perth, Not set

Alfred Hospital, Prahran, Not set

Adventist Health Care Limited trading as San Clinical Trials Unit, Wahroonga, Not set

UZA, Antwerp, Not set

A.Z. Sint Jan, Brugge, Not set

UCL - Saint Luc, Brussels, Not set

UZ Gent - departement oncologie, Gent, Not set

UZ Leuven Gasthuisberg, Leuven, Not set

UCL Mont-Godinne, Yvoir, Not set

Ministerio da Saude Instituto Nacional do Cancer, Rio De Janeiro, Not set

Santa Casa da Misericórdia da Bahia - Hospital Santa Isabel, Salvador, Not set

Instituto de Ensino e Pesquisa São Lucas, Sao Paulo, Not set

Jewish General Hospital, Montreal, Quebec

Peking University People s Hospital, Beijing, Not set

Peking University Third Hospital, Beijing, Not set

Peking University First Hospital, Beijing, Not set

West China Hospital Sichuan University, Chengdu, Not set

Fujian Medical University, Fuzhou, Not set

Sun Yat-sen University Cancer Hospital, Guangzhou, Not set

Zhejiang University First Hospital, Hangzhou, Not set

Ruijin Hospital, Shanghai, Not set

Tangdu hospital the Fourth Military Medical, Shanxi, Not set

The First Affliated Hospital of Soochow University, Suzhou, Not set

The Institute of Hematological disease, Tianjin, Not set

Wuhan Union Hospital, Wuhan, Not set

Fundacion Santa Fe, Bogota, Not set

Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Not set

Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Brno, Not set

Fakultni nemocnice Kralovske Vinohrady - Interni hematologicka klinika, Praha 10, Not set

Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Not set

Hopital Henri Mondor, Creteil, Not set

Hôpital E. Muller, Mulhouse, Not set

Hopital Necker Enfants Malades, Paris cedex 15, Not set

HOPITAL SAINT LOUIS - Hematology / Oncology, Paris, Not set

Hopital Haut Leveque Service Maladie Du Sang, Pessac, Not set

CH LYON SUD - Hematology, Pierre Benite, Not set

CHU de Tours, Tours, Not set

Vivantes Klinikum Spandau-Klinik f. Innere Medizin Hämatologie/Onkologie/Gastroenterologie - Germany, Berlin, Not set

Universitätsklinikum Carl Gustav Carus; Med. Klinik und Poliklinik I - Hämatologische Ambulanz, Haus, Dresden, Not set

Universitätsklinikum Essen; Klinik f. Hämatologie- Germany, Essen, Not set

Justus-Liebig-Universitaet - Medizinische Klinik IV, Haematologie, Gießen, Not set

Universitätsklinikum Heidelberg Med. Klinik IV, Heidelberg, Not set

Universitätsklinikum des Saarlandes, Homburg/Saar, Not set

Gemeinschaftspraxis Dres. Uhle/Müller/Kröning/Jentsch-Ullrich - Germany, Magdeburg, Not set

OnkoNet Marburg GmbH, Marburg, Not set

Universitätsklinikum für Innere Med. III_Hämatologie, Onkologie...- Germany, Ulm, Not set

Laiko General Hospital - 1st department of Internal Medicine, Athens, Not set

G Papanikolaou Hospital of Thessaloniki, Thessalonikis, Not set

Semmelweis Egyetem, I. Belgyogyaszati Klinika, Budapest N/a, Not set

Szegedi Tudomanyegyetem II. Belgyogyaszati Klinika, Szeged, Not set

St James's Hospital, Dublin, Not set

Haemek Medical Center, Afula, Not set

Hillel Yaffe Medical Center - Oncology, Hadera, Not set

Rambam Health Care Campus, Haifa, Not set

Rabin Medical Center Beilinson Campus, Petah Tikva, Not set

Sheba Medical Center, Ramat-Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA - UNIVERSITà ''LA SAPIENZA'', Roma, Not set

A.O.Citta della Salute e della Scienza di Torino, Torino, Not set

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo ku, Not set

Hiroshima University Hospital, Hiroshima shi, Not set

Hokkaido University Hospital, Sapporo-shi, Not set

National Cancer Center, Goyang-Si, Not set

The Catholic University of Korea Seoul St Mary s Hospital, Seoul, Not set

Oaxaca Site Management Organization S.C., Oaxaca, Not set

VU medisch centrum - Afd.Interne - INT, Amsterdam, Not set

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza, Brzozow, Not set

Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich, Chorzow, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Pratia MCM Krakow, Krakow, Not set

Oddzial Hematologii, Opole, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka, Slupsk, Not set

Katedra I Klinika Hematologii Nowotworow Krwi I Transplantacji Szpiku, Wroclaw, Not set

Instituto Portugues de Oncologia, Lisboa, Not set

Hospital De Santa Maria, Lisbon, Not set

Instituto Portugues de Oncologia, Porto, Not set

Auxilio Mutuo Cancer Center, San Juan, Not set

Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Not set

Chelyabinsk Regiona Onc. Center, Chelyabinsk, Not set

Emergency Hospital of Dzerzhinsk, Dzerzhinsk, Not set

Cancer Research Center, Moscow N/a, Not set

S.P. Botkin Moscow City Clinical Hospital, Moscow, Not set

Regional Clinical Hospital n.a.Semashko, Nizhni Novgorod, Not set

Medical Scientific Radiology - Center, Obninsk, Not set

Perm Medical Sanitary Unit#1, Perm, Not set

Republican Hospital named by V.A.Baranova, Petrozavodsk, Not set

Rostov Research Institute of Oncology, Rostov-Na-Donu, Not set

Ryazan Regional Clinical Hospital, Ryazan, Not set

Leningrad region clinical hospital, Saint, Not set

Samara Region Clinical Hospital, Samara, Not set

Federal Center of Heart, Blood and Endocrinology, Sankt-Peterburg, Not set

Oncological dispensary #2, Sochi, Not set

City Clinical Oncology Dispensary, St. Petersburg, Not set

Clinical Research Institute of Hematology and Transfusiology, St.-Petersburg, Not set

Oncology Dispensary of Komi Republic, Syktyvkar, Not set

Hospital Vall d'Hebron, Barcelona N/a, Not set

Inst. Cat. Doncologia-H Duran I Reynals, L'hospitalet De Llobregat, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Hosp. Univ. Infanta Leonor, Madrid, Not set

Fundacion Jimenez Diaz, Madrid, Not set

Clinica Universitaria de Navarra, Pamplona N/a, Not set

Hospital Clinico Universitario Salamanca, Salamanca, Not set

Sahlgrenska University hospital, Hematology Dept, Göteborg, Not set

Skanes universitetssjukhus, Lund, Not set

Karolinska Universitetssjukhuset Solna, Centrum för Hematologi, Stockholm, Stockholm, Not set

Changhua Cristian Hospital, Changhua County, Not set

Ankara University, Ankara, Not set

American Hospital, Istanbul, Not set

Istanbul University, Istanbul, Not set

Dokuz Eylul Universitesi Tip Fakultesi, Izmir, Not set

Erciyes University, Kayseri, Not set

Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Not set

Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Not set

SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine, Kharkiv, Not set

Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy, Not set

State Institution Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine, Kiev, Not set

Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine, Lviv, Not set

Vinnytsya Regional Clinical Hospital named after M.I.Pirogov, Vinnitsa, Not set

University Hospitals Birmingham NHS Trust,, Birmingham, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Colchester Hospital University NHS, Colchester, Not set

Beatson West Of Scotland Cancer Centre, Glasgow, Not set

St James's Institute of Oncology, Leeds, Not set

Leicester Royal Infirmary - Haematology, Leicester, Not set

St Bartholomew's Hospital - Dept of Haematology, London, Not set

University College London Hospitals NHSFT, London, Not set

Kings College Hospital, London, Not set

Christie Hospital, Manchester, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Derriford Hospital, Plymouth, Not set

Royal Hallamshire Hospital, Sheffield, Not set

Southampton General Hospital, Southampton, Not set

Royal Marsden Hospital (Sutton), Sutton, Not set

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Waldenstrom Macroglobulinemia, Chronic Graft Versus Host Disease

Learn More ›

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019

Recruiting

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of CLL. Study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receiv... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/21/2025

Locations: Arizona Oncology - Tucson - Rudasill /ID# 267552, Tucson, Arizona +63 locations

Arizona Oncology - Tucson - Rudasill /ID# 267552, Tucson, Arizona

UCSF FRESNO/Community Cancer Institute /ID# 270874, Clovis, California

Valkyrie Clinical Trials /ID# 268151, Los Angeles, California

Rocky Mountain Cancer Centers - Aurora /ID# 267549, Aurora, Colorado

Yale University School of Medicine /ID# 266224, New Haven, Connecticut

Malcolm Randall V.A. Medical Center /ID# 267825, Gainesville, Florida

Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 266713, Jacksonville, Florida

Mid Florida Hematology And Oncology Center /ID# 269159, Orange City, Florida

Comprehensive Hematology Oncology /ID# 267644, Saint Petersburg, Florida

Springfield Clinic /ID# 270145, Springfield, Illinois

Northwest Cancer Center - Dyer Clinic /ID# 268478, Dyer, Indiana

University of Iowa Health Care /ID# 267206, Des Moines, Iowa

Willis-Knighton Medical Center /ID# 270569, Shreveport, Louisiana

American Oncology Partners of Maryland /ID# 266445, Bethesda, Maryland

Maryland Oncology Hematology - Silver Spring /ID# 267557, Silver Spring, Maryland

Saint Luke's Hospital of Kansas City /ID# 267270, Kansas City, Missouri

Cleveland Clinic Main Campus /ID# 271292, Cleveland, Ohio

Oklahoma Cancer Specialists and Research Institute /ID# 267643, Tulsa, Oklahoma

Willamette Valley Cancer Institute and Research Center /ID# 266326, Eugene, Oregon

Lifespan Cancer Institute - Providence /ID# 266550, Providence, Rhode Island

Texas Oncology - Austin Midtown /ID# 268152, Austin, Texas

University of Texas - Southwestern Medical Center /ID# 266528, Dallas, Texas

Virginia Cancer Specialists - Gainesville /ID# 268155, Gainesville, Virginia

Vista Oncology - East Olympia /ID# 267337, Olympia, Washington

Northwest Medical Specialties Tacoma /ID# 266327, Tacoma, Washington

West Virginia University School of Medicine /ID# 267645, Morgantown, West Virginia

Calvary Mater Newcastle /ID# 267408, Waratah, New South Wales

Townsville University Hospital /ID# 266954, Townsville, Queensland

St Vincent's Hospital - Melbourne /ID# 270027, Fitzroy, Victoria

Royal Perth Hospital /ID# 266906, Perth, Western Australia

Centre Hospitalier Universitaire de Saint Etienne - Hopital Nord /ID# 266319, St-Priest-en-Jarez, Loire

CHR Metz-Thionville - Hôpital de Mercy /ID# 266852, Ars Laquenexy, Moselle

Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 266270, Creteil, Paris

Hopitaux Universitaires Paris Centre-Hopital Cochin /ID# 267438, Paris CEDEX 14, Paris

Centre Antoine-Lacassagne /ID# 266894, Nice, Provence-Alpes-Cote-d Azur

Centre Hospitalier de la Côte Basque /ID# 266847, Bayonne, Pyrenees-Atlantiques

Centre Hospitalier Métropole Savoie - Site Hôpital de Chambéry /ID# 266854, Chambery CEDEX, Savoie

CHU d'Amiens-Picardie - Hôpital Sud /ID# 266849, Amiens CEDEX 1, Somme

Centre Hospitalier d'Argenteuil Victor Dupouy /ID# 266322, Argenteuil, Not set

Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 266272, Orléans, Not set

Olympion General Clinic /ID# 266819, Patras, Achaia

Evangelismos Hospital /ID# 266815, Athens, Attiki

General Hospital of Athens Laiko /ID# 266813, Athens, Attiki

University General Hospital Attikon /ID# 266814, Athens, Attiki

University General Hospital of Alexandroupoli /ID# 266816, Alexandroupoli, Evros

Pan American Center for Oncology Trials /ID# 266243, Rio Piedras, Not set

Clinical Hospital Center Zvezdara /ID# 266560, Belgrade, Beograd

University Clinical Center Serbia /ID# 266579, Belgrade, Beograd

Clinical Hospital Center - Bežanijska Kosa /ID# 266567, Belgrade, Beograd

University Clinical Center Nis /ID# 266580, Niš, Nisavski Okrug

University Clinical Center Kragujevac /ID# 266568, Kragujevac, Sumadijski Okrug

Institute for Oncology of Vojvodina /ID# 266556, Sremska Kamenica, Vojvodina

University Clinical Center Vojvodina /ID# 266674, Novi Sad, Not set

Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 267164, Santiago de Compostela, A Coruna

Hospital Universitario Puerta de Hierro - Majadahonda /ID# 266967, Majadahonda, Madrid

Clinica Universidad de Navarra - Pamplona /ID# 267762, Pamplona, Navarra

CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 266969, Madrid, Not set

Hospital MD Anderson Cancer Center Madrid /ID# 267167, Madrid, Not set

Hospital Universitario Virgen del Rocio /ID# 266968, Sevilla, Not set

Kaohsiung Chang Gung Memorial Hospital /ID# 267046, Kaohsiung City, Kaohsiung

National Taiwan University Hospital /ID# 267017, Taipei City, Taipei

China Medical University Hospital /ID# 267018, Taichung, Not set

Linkou Chang Gung Memorial Hospital /ID# 267045, Taoyuan City, Not set

Nottingham City Hospital /ID# 266991, Nottingham, Nottinghamshire

Conditions: Chronic Lymphocytic Leukemia

Learn More ›

A Ph2 Study of Glofitamab Alone or With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

NCT06043674

Recruiting

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: * Glofitamab (a T-cell bispecific humanized monoclonal antibody) * Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) * Polatuzumab vedotin (an ant... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/19/2025

Locations: Brigham and Women's Hospital, Boston, Massachusetts +3 locations

Conditions: Chronic Lymphocytic Leukemia, Richter's Transformation

Learn More ›

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

NCT06333262

Recruiting

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/19/2025

Locations: New England Cancer Specialists, Scarborough, Maine +3 locations

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Learn More ›

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

NCT05031897

Recruiting

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/14/2025

Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hodgkin Lymphoma, Myelofibrosis, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Polycythemia Vera, Small Lymphocytic Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphatic System Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.

NCT06524375

Recruiting

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/02/2025

Locations: Highlands Oncology Group, Springdale, Arkansas +18 locations

Conditions: Chronic Lymphocytic Leukemia

Learn More ›

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT05602363

Recruiting

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/23/2025

Locations: UC Irvine Health, Orange, California +9 locations

Conditions: B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

Learn More ›

Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant

NCT03622788

Recruiting

This phase I/II trial studies how well cytokine-treated veto cells work in treating patients with hematologic malignancies following stem cell transplant. Giving chemotherapy and total-body irradiation before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, whit... Read More

Gender:

ALL

Ages:

Between 12 years and 75 years

Trial Updated:

04/23/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Bone Marrow Failure, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma

Learn More ›

25 - 36 of 71